To KK - Search Results

1

Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration.

Ierano C, Basseville A, To KK, Zhan Z, Robey RW, Wilkerson J, Bates SE, Scala S. Ierano C, et al. Among authors: to kk. Cancer Biol Ther. 2013 Feb;14(2):175-83. doi: 10.4161/cbt.22957. Epub 2012 Nov 28. Cancer Biol Ther. 2013. PMID: 23192271 Free PMC article.

2

Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.

To KK, Zhan Z, Bates SE. To KK, et al. Mol Cell Biol. 2006 Nov;26(22):8572-85. doi: 10.1128/MCB.00650-06. Epub 2006 Sep 5. Mol Cell Biol. 2006. PMID: 16954373 Free PMC article.

3

Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Liao Z, Robey RW, Guirouilh-Barbat J, To KK, Polgar O, Bates SE, Pommier Y. Liao Z, et al. Among authors: to kk. Mol Pharmacol. 2008 Feb;73(2):490-7. doi: 10.1124/mol.107.041178. Epub 2007 Nov 5. Mol Pharmacol. 2008. PMID: 17984197 Free PMC article.

4

Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.

To KK, Polgar O, Huff LM, Morisaki K, Bates SE. To KK, et al. Mol Cancer Res. 2008 Jan;6(1):151-64. doi: 10.1158/1541-7786.MCR-07-0175. Mol Cancer Res. 2008. PMID: 18234970 Free PMC article.

5

Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.

To KK, Zhan Z, Litman T, Bates SE. To KK, et al. Mol Cell Biol. 2008 Sep;28(17):5147-61. doi: 10.1128/MCB.00331-08. Epub 2008 Jun 23. Mol Cell Biol. 2008. PMID: 18573883 Free PMC article.

6

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.

To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE. To KK, et al. Mol Cancer Ther. 2009 Oct;8(10):2959-68. doi: 10.1158/1535-7163.MCT-09-0292. Mol Cancer Ther. 2009. PMID: 19825807 Free PMC article.

7

Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway.

To KK, Robey R, Zhan Z, Bangiolo L, Bates SE. To KK, et al. Mol Cancer Res. 2011 Apr;9(4):516-27. doi: 10.1158/1541-7786.MCR-10-0270. Epub 2011 Feb 25. Mol Cancer Res. 2011. PMID: 21357443 Free PMC article.

8

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.

Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L. Wu S, et al. Mol Cancer. 2021 Jan 18;20(1):17. doi: 10.1186/s12943-021-01307-9. Mol Cancer. 2021. PMID: 33461557 Free PMC article.

9

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.

Yang K, Fu K, Zhang H, Wang X, To KKW, Yang C, Wang F, Chen ZS, Fu L. Yang K, et al. Among authors: to kkw. Mol Cancer. 2024 Sep 28;23(1):209. doi: 10.1186/s12943-024-02129-1. Mol Cancer. 2024. PMID: 39342174 Free PMC article.

10

The RNA Binding Protein HuR: A Promising Drug Target for Anticancer Therapy.

Wu M, Tong CWS, Yan W, To KKW, Cho WCS. Wu M, et al. Curr Cancer Drug Targets. 2019;19(5):382-399. doi: 10.2174/1568009618666181031145953. Curr Cancer Drug Targets. 2019. PMID: 30381077 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

519 results

Search Page

Filters